Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection

被引：0

作者：

Chen, Yiwen ^{[1
]}

Shen, Yan ^{[1
]}

Zhang, Min ^{[1
]}

Wu, Jian ^{[1
]}

Gao, Shunliang ^{[1
]}

Que, Risheng ^{[1
]}

Yu, Jun ^{[1
]}

Tang, Xiaofeng ^{[1
]}

Bai, Xueli ^{[1
]}

Liang, Tingbo ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.571

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：571 / 571

页数：1

共 50 条

[41] The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction
Peng, N.
Su, J-Y.
Liu, S.
Li, L.
Ma, L.
Zhong, J-H.
ANNALS OF ONCOLOGY, 2024, 35 : S1487 - S1487
[42] Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Nan Zhang
Xu Yang
Mingjian Piao
Ziyu Xun
Yunchao Wang
Cong Ning
Xinmu Zhang
Longhao Zhang
Yanyu Wang
Shanshan Wang
Jiashuo Chao
Zhenhui Lu
Xiaobo Yang
Hanping Wang
Haitao Zhao
Biomarker Research, 12
[43] Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Zhang, Nan
Yang, Xu
Piao, Mingjian
Xun, Ziyu
Wang, Yunchao
Ning, Cong
Zhang, Xinmu
Zhang, Longhao
Wang, Yanyu
Wang, Shanshan
Chao, Jiashuo
Lu, Zhenhui
Yang, Xiaobo
Wang, Hanping
Zhao, Haitao
BIOMARKER RESEARCH, 2024, 12 (01)
[44] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study
Wang, Jiabei
Peng, Tao
Liu, Chang
Zhang, Ling
Zhu, Guangzhi
Zhang, Xiaogang
Wang, Xiaoqian
Liu, Lianxin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
Yao, Junlin
Zhu, Xudong
Wu, Zhiheng
Wei, Qing
Cai, Yibo
Zheng, Yu
Hu, Xinyu
Hu, Hong
Zhang, Xiangyu
Pan, Hongming
Zhong, Xian
Han, Weidong
CANCER MEDICINE, 2022, 11 (19): : 3612 - 3622
[46] Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: Results of a multicenter study
Regimbeau, JM
Abdalla, EK
Vauthey, JN
Lauwers, GY
Durand, FO
Nagorney, DM
Ikai, I
Yamaoka, Y
Belghiti, J
JOURNAL OF SURGICAL ONCOLOGY, 2004, 85 (01) : 36 - 41
[47] Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
Zhang, Wenwen
Hu, Bingyang
Han, Jun
Wang, Zhanbo
Ma, Guangyu
Ye, Huiyi
Yuan, Jing
Cao, Junning
Zhang, Ze
Shi, Jihang
Chen, Mingyi
Wang, Xun
Xu, Yinzhe
Cheng, Yanshuang
Tian, Lantian
Wang, Hongguang
Lu, Shichun
FRONTIERS IN ONCOLOGY, 2021, 11
[48] Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?
Akateh, Clifford
Pawlik, Timothy M.
Cloyd, Jordan M.
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (20)
[49] A RANDOMIZED PILOT PHASE II STUDY OF THALIDOMIDE AS ADJUVANT THERAPY IN PATIENT WITH HIGH RECURRENCE RISK HEPATOCELLULAR CARCINOMA
Ho, M. -C.
Hu, R. -H.
Ho, C. -M.
Chen, C. -N.
Chang, K. -J.
Lee, P. -H.
JOURNAL OF HEPATOLOGY, 2011, 54 : S35 - S35
[50] Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
Meng Yang
Jingwen Zhang
Dongqun Wei
Tianyi Yu
Zeyu Chen
Xin Liu
Haitao Zhu
BMC Cancer, 24

← 1 2 3 4 5 →